Sam Waksal's ROCK2 biotech Graviton hauls in $35M boost from Enavate
07 Dec 2023
Investors are pouring more money into a biotech created by industry veteran Sam Waksal, founder of ImClone Systems, Kadmon, MeiraGTx and Équilibre Biopharmaceuticals, and who has sold multiple companies to Big Pharma.
The latest bet, clinical-stage ROCK2 startup Graviton Bioscience, has landed an additional $35 million in funding, coming from lead investor Patient Square Capital’s Enavate Sciences, Waksal told Endpoints News on Thursday afternoon. He said the investment gives Graviton a higher valuation than during the biotech’s prior financings from Cormorant, Pontifax and other undisclosed backers, who had previously funded the company with at least $30 million.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.